Cataplexy may involve any skeletal muscles, except for the diaphragm and extraocular muscles, with effects ranging from partial muscle weakness to complete paralysis. There is substantial phenotypic variation in the presentation of cataplexy. This review provides a comprehensive report on the research evidence for pitolisant in the treatment of cataplexy. The only medications approved for the treatment of both EDS and cataplexy in patients with narcolepsy are pitolisant (Wakix) and oxybate compounds (sodium oxybate calcium, magnesium, potassium, and sodium oxybates ). The management of narcolepsy (with or without cataplexy) usually requires long-term pharmacotherapy, and available treatments address one or more symptoms.
The International Classification of Sleep Disorders, third edition (ICSD-3) classifies narcolepsy as narcolepsy type 1 (NT1, formerly ‘narcolepsy with cataplexy’) or narcolepsy type 2 (NT2, formerly ‘narcolepsy without cataplexy’). Cataplexy – the sudden loss of muscle tone often triggered by strong emotion – is the most specific symptom of narcolepsy and, if unambiguously identified, is an accurate diagnostic marker for the disease. periods of unrelenting sleep pressure and/or unintended lapses into drowsiness or sleep) is a required component of the diagnostic criteria for narcolepsy. sleep paralysis, hypnagogic hallucinations), and disrupted nighttime sleep, which are indicative of sleep-wake instability. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS), cataplexy, other manifestations of rapid eye movement (REM) sleep dysregulation (i.e.
0 kommentar(er)
